2011

Identification of a Second Mimicry Epitope from *Acanthamoeba castellanii* that Induces CNS Autoimmunity by Generating Cross-Reactive T Cells for MBP 89–101 in SJL Mice

Chandirasegaran Massilamany  
*University of Nebraska - Lincoln*

Oluwatoyin A. Asojo  
*University of Nebraska Medical Center, oasojo@unmc.edu*

Arunakumar Gangaplara  
*University of Nebraska - Lincoln*

David J. Steffen  
*University of Nebraska-Lincoln, dsteffen1@unl.edu*

Jay Reddy  
*University of Nebraska - Lincoln, jayreddy@unl.edu*  
*Follow this and additional works at: [http://digitalcommons.unl.edu/vbsjayreddy](http://digitalcommons.unl.edu/vbsjayreddy)*

Part of the *Biological Phenomena, Cell Phenomena, and Immunity Commons, Medical Biochemistry Commons, Medical Molecular Biology Commons*, and the *Nervous System Diseases Commons*

[http://digitalcommons.unl.edu/vbsjayreddy/19](http://digitalcommons.unl.edu/vbsjayreddy/19)

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Jay Reddy Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Identification of a Second Mimicry Epitope from *Acanthamoeba castellanii* that Induces CNS Autoimmunity by Generating Cross- Reactive T Cells for MBP 89–101 in SJL Mice

Chandirasegaran Massilamany¹, Oluwatoyin A. Asojo², Arunakumar Gangaplara¹, David Steffen¹, and Jay Reddy¹

¹School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, U.S.A.; ²Department of Pathobiology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.

Correspondence to: J. Reddy, School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, U.S.A.; E-mail: jayreddy@unl.edu

Received April 4, 2011; accepted September 20, 2011; advance access publication was made available November 4, 2011.

Abstract

We had previously reported that *Acanthamoeba castellanii* (ACA) contains a mimicry epitope for proteolipid protein 139–151 capable of inducing central nervous system (CNS) autoimmunity in SJL/J mice. We now present evidence that ACA also contains a mimicry epitope for myelin basic protein (MBP) 89–101, a derivative from amoebic nicotinamide adenine dinucleotide dehydrogenase subunit 2 (NAD). The epitope, NAD 108–120, contains a discontinuous stretch of six amino acids in the core region (VVFKNIIILGFL) sharing 46% identity with MBP 89–101 (VHFFKNIVTPRP; identical residues are underlined). SJL mice immunized with NAD 108–120 develop encephalomyelitis similar to the disease induced by the cognate peptide. We demonstrate that NAD 108–120 induces T cells that cross-react with MBP 89–101; the antigen-sensitized T cells, which produce predominantly T helper (T<sub>H</sub>) 1 and T<sub>H</sub>17 cytokines, transfer disease in naive SJL recipients reminiscent of the disease induced with MBP 89–101. This is the first report to demonstrate that a solitary microbe can induce CNS autoimmunity by generating cross-reactive T cells for multiple myelin antigens.

Keywords: Experimental autoimmune encephalomyelitis, Multiple sclerosis, Molecular mimicry, Myelin basic protein, *Acanthamoeba castellanii*

Introduction

Multiple sclerosis (MS) is believed to be an autoimmune disease of the central nervous system (CNS), and autoreactive T cells and B cells have been implicated in the disease pathogenesis (1, 2). Three candidate autoantigens—myelin proteolipid protein (PLP), myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG)—have been identified in MS pathogenesis, and MS patients show varying degrees of T cell and antibody responses to all three (1, 3–5). The importance of these antigens has been well studied in the rodent models of experimental autoimmune encephalomyelitis (EAE) by inducing the disease with the immunodominant epitopes of myelin antigens, the phenotypes of which vary with different genetic backgrounds. For example, MBP<sub>89</sub>–101 induces the monophasic form of EAE in SJL/J mice. By using PLP 139–151/MBP 89–101, we recently identified a novel epitope from *Acanthamoeba castellanii* (ACA), 83–95, which mimics for PLP 139–151, we recently identified a novel epitope from *Acanthamoeba castellanii* (ACA), 83–95, which induces EAE in SJL mice by generating cross-reactive cells for PLP 139–151 (19). We also demonstrated that the pathogenicity of ACA 83–95-induced PLP-specific cells differs by gender but is independent of cytokine responses, in that the cross-reactive cells generated in males fail to induce the disease in females but not vice versa, suggesting modulation of cross-reactive immune responses by sex hormones (20). Regardless of gender, however, the TCR V<sub>B</sub> usage of cross-reactive T cells induced with ACA 83–95 differs from that of cells induced with PLP 139–151. By using PLP 139–151/IA<sup>A</sup> tetramers, we showed that the TCR V<sub>B</sub>2-expressing PLP
139–151-specific CD4 cells are skewed in mice immunized with ACA 83–95, indicating that exposure to microbial mimics can lead to the selective expansion of T cell clones that differ from those generated by cognate epitopes (20). In this report, we present evidence that ACA also contains a mimicry epitope for MBP 89–101 and that the epitope spanning 108–120 amino acids represents the nicotinamide adenine dinucleotide dehydrogenase subunit 2 (NAD) of *Acanthamoeba*. We demonstrate that NAD 108–120 induces clinical and histological features of EAE similar to those induced by the cognate peptide in SJL mice by generating cross-reactive T cells for MBP 89–101 and pro-inflammatory cytokines that favor CNS autoimmunity.

**Methods**

**Mice**

Four- to six-week-old female SJL/J (H-2b) mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, U.S.A.). The mice were maintained in accordance with the animal protocol guidelines of the University of Nebraska-Lincoln, Lincoln, Nebraska, U.S.A.

**Identification of NAD 108–120**

Using the LALIGN server (http://www.ch.embnet.org/software/LALIGN_form.html), we searched for identical sequences of MBP 89–101 (VHFFKNIVTPRTP) by comparing ~200 known protein sequences of ACA retrieved from National Center for Biotechnology Information protein database (http://www.ncbi.nlm.nih.gov/). This search resulted in the identification of one epitope spanning the amino acids 108–120 within the NAD of ACA (VVFKNIIIGFL). All the data were generated using NAD 108–120, except for the homology model for which we used the sequence of NAD 104–118 (NDAAVVFKNIIIG) by including four additional residues at the N-terminal end and excluding two residues at the C-terminal end from NAD 108–120. The sequence length of NAD 104–118 is consistent with that of MBP 85–99 used in the structural study (21).

**Derivation of NAD 104–118/HLA-DR2 homology model**

To determine differences between MBP 85–99 and NAD 104–118 with respect to their MHC-contact residues within the binding pockets of HLA-DR2 molecule, we used the crystal structure of HLA-DR2 (DRA, DRB1*1501) complexed with human MBP 85–98 or MBP 86–99 as a reference model (21). The coordinates of these structures (1BX2) were obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (http://www.rcsb.org) and used with the kind permission from Dr. Kai Wucherpfennig, Harvard University, Boston, Massachusetts, U.S.A. The MBP 85–99 reference model was generated by averaging the monomers from the original crystal structure complexed with MBP 85–98 for one monomer and with MBP 86–99 for the other. The averaged structure was three-dimensional-protonated and energy-minimized using MMFF94x restraints within MOE software to yield an optimized MBP 85–99/HLA-DR2 structure (Chemical Computing group, Montreal, Canada). The optimized MBP 85–99/HLADR2 model was then used as a template to generate a homology model for HLA-DR2 molecule complexed with NAD 104–118, and the structure was optimized using MOE as described above. The figures of the model were generated using PyMOL software (http://www.pymol.org).

**Peptide synthesis and immunization procedures**

NAD 108–120, MBP 89–101 and Theiler’s murine encephalomyelitis virus (TMEV) 70–86 (WTTSQEAFSIRIPLP) were synthesized on 9-fluorenylmethyloxyacylonylamidic chemistry (Neopeptide, Cambridge, Massachusetts, U.S.A.). All peptides were HPLC-purified (>90%) and confirmed by mass spectroscopy and then dissolved in sterile 1× PBS (MBP 89–101) or 1× PBS/dimethyl sulfoxide (DMSO) (NAD 108–120). For disease induction, peptides dissolved in 1× PBS were emulsified in complete Freund’s adjuvant (CFA) supplemented with *Mycobacterium tuberculosis* (MTB) H37RA extract (Difco Laboratories, Detroit, Michigan, U.S.A.) to a final concentration of 5 mg ml⁻¹, and the peptide emulsions were administered twice in the sternal and inguinal regions with an interval of 7 days (6). In addition, pertussis toxin (PT; List Biological Laboratories, Campbell, California, U.S.A.) was administered (400 ng per mouse) intraperitoneally on day 0 and day 2 post-immunization after the first immunization (6, 8, 22) only. To measure recall responses, MBP 89–101 and NAD 108–120 dissolved respectively, in 1× PBS and DMSO were emulsified in CFA containing no additional MTB extract and administered as above.

**Clinical scoring and histopathology**

After EAE induction, the mice were monitored for clinical signs of disease and scored as described previously (8, 22): 0, healthy; 1, decreased tail and body tone; 2, a clumsy but otherwise normal gait; 3, definite weakness of one or more limbs; 4, a paraplegic or monoplegic state and 5, a paraplegic state. Animals were euthanized during recovery or upon termination on day 30 post-immunization. Brain and spinal cords were collected in 10% phosphate-buffered formalin and analyzed for histological evidence of inflammatory changes (19, 23). After fixation, two brain sections were made; one included cerebrum and hippocampus, and the second included cerebellum and brainstem. In the spinal cord, three sections were made from each segment (cervical, thoracic, lumbar and sacral). All the tissues were stained by hematoxylin and eosin staining. Tissues were blinded to treatment, lesion type was characterized and severity was scored. Severity scores were obtained by counting inflammatory foci in both meninges and parenchyma for all sites. Inflammation was primarily classified as lymphocytic, suppurative or mixed (19, 20). For statistical analysis, counts were added across all sections of brain and spinal cord for each mouse.

**Adoptive transfer EAE**

Groups of five mice were immunized twice with MBP 89–101 or NAD 108–120 (200 μg per mouse) with a 7-day interval between immunizations; 7 days after the second immunization, the animals were killed, and LNC were prepared from the draining lymph nodes (LNs). LNC were stimulated with Concanavalin-A (Con-A) at a concentration of 1 μg ml⁻¹ for 2 days as described previously (6, 24). Viable lymphoblasts were harvested by Ficoll-Hypaque density-gradient centrifugation, and 60 × 10⁶ cells were administered intraaperitoneally into groups of five naive SJL mice. Additionally, each animal received PT (400 ng) on days 0 and 2 post-transfer, and the animals were monitored for clinical signs of EAE and scored.
as above (8, 22, 6). The experiments were terminated on day 21 postinoculation, and the CNS tissues were harvested for histology (19, 20).

**Proliferation assay**

Groups of mice were immunized with MBP 89–101 or NAD 108–120, and after 10 days, the animals were killed and the draining LN collected to prepare single-cell suspensions. LNC were stimulated with MBP 89–101, NAD 108–120 and TMEV 70–86 (0–100 lg/ml) at a cell density of 5 × 10⁶ cells/ml for 2 days in RPMI medium supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 4 mM L-glutamine, 1× each of nonessential amino acids and vitamin mixture and 100 U/ml penicillin-streptomycin (Lonza, Walkersville, Maryland, U.S.A.). Cultures were then pulsed with 1 μCi of [H]thymidine per well; 16 h later, the proliferative responses were measured as counts per minute (c.p.m.) using a Wallac liquid scintillation counter (Perkin Elmer, Waltham, Massachusetts, U.S.A.) hereafter called growth medium. We further verified these responses by second-round of re-stimulation with each peptide. LNC obtained from immunized mice were first stimulated with MBP 89–101 or NAD 108–120 (20 μg ml⁻¹) for 2 days and the cells were maintained in growth medium containing IL-2. Viable cells were harvested on day 4 post-stimulation; rested for ~10 to 14 days and the proliferative responses were measured after re-stimulating the cells with the indicated peptides as above.

**Intracellular cytokine staining**

Mice were immunized with MBP 89-101 or NAD 108–120 and 10 days later, the animals were killed and LN were harvested to prepare LNC. Cells were stimulated with the corresponding peptides for 2 days (20 μg ml⁻¹) and the cultures were maintained in IL-2 medium. Viable lymphoblasts were harvested on day 4 and stimulated for 4.5 h with phorbol 12-myristate 13-acetate (PMA) (20 ng ml⁻¹) and ionomycin (300 ng ml⁻¹) (Sigma–Aldrich, St Louis, Missouri, U.S.A.) in the presence of 2 mM monensin (GolgiStop; BD Pharmingen, San Diego, California, U.S.A.). After staining with anti-CD4 and 7-aminoactinomycin D (7-AAD; Invitrogen, Eugene, Oregon, U.S.A.), cells were fixed, permeabilized and stained with cytokine antibodies or isotype controls (eBioscience, San Diego, California, U.S.A.; 19, 20). Cells were acquired by flow cytometry (FC, FACS Scan; BD Pharmingen), and the frequencies of cytokine-secreting cells were analyzed in the live (7-AAD) CD4+ subset using FlowJo software (Tree star, Ashland, Oregon, U.S.A.; 19). The clones of cytokine antibodies used were: IL-2 (JES6-5H4), IL-4 (11B11), IL-10 (JES5-16E3), IFN-γ (XMG1.2), IL-17A (eBio17B7), IL-17F (eBio 18F10), granulocyte macrophage-colony stimulating factor (GM-CSF) (MP122E9) and IL-22 (140301) (R&D Systems, Minneapolis, Minnesota, U.S.A.).

**Cytokine ELISA**

Supernatants harvested from the above cultures on day 2 were analyzed for cytokines by ELISA (19). The clones of the capture and detection antibody pairs used were: IL-2 (JES6-1A12/JES6-5H4), IL-4 (11B11/BVD6-24G2), IL-10 (JES5-16E3/JES5-2A5), IL-17A (eBio17CK15A5/eBio17B7), IFN-γ (AN-18/R4-6A2), IL-22 (IH8-PWSR/IL-22-JOP) and GM-CSF (MP1-22E9/MP1-31G6) (eBioscience).

**Analysis of TCR vβ usage**

LNC harvested from the mice immunized with MBP 89–101 or NAD 108–120 were stimulated with the corresponding peptides for 2 days (20 μg ml⁻¹), and the cultures were maintained in IL-2 medium. Cells were harvested on day 4 post-stimulation with peptides and stained with a panel of anti-mouse TCR vβ antibodies: vβ 2, 3, 4, 5.1, 5.2, 6, 7, 8.1, 8.2, 8.3, 9, 10b, 11, 12, 13, 14 and 17a (BD Pharmingen), anti-CD4 and 7-AAD. After acquiring the cells by FC, percentages of TCR vβ+ cells were enumerated in the live (7-AAD) CD4 population (20).

**Statistics**

Comparisons of histological disease between groups for inflammatory lesions in the brain and spinal cords were analyzed by two-sided Wilcoxon rank sum test (Mann–Whitney U-test). Differences in the cumulative neurological scores of animals with EAE and cytokine secretion with respect to T helper (Tₜ)₁, Tₜ₂ and Tₜ₁ seven subsets between groups were compared by student’s t-test. P < 0.05 values were considered significant.

**Results**

**NAD 108–120 has the structural characteristics of binding to HLA-DR2 molecules**

By sequence comparisons, we identified NAD 108–120 as the mimicry epitope for MBP 89–101 showing a similarity of 46.2% and containing a discontinuous stretch of six amino acids (VYFKKNI) in the core region [Figure 1A(i)]. This region within human MBP 85–99 represents an epitope center for recognition by both TCR and auto-antibodies (5). Further more, by crystal study of HLA-DR2 (DRA*0101, DRB1*1501) complexed with human MBP 85–99, the critical MHC-contact residues in MBP 85–99 have been well characterized (21). These include Val89 and Phe92 as primary anchor residues, the latter being the most critical and they bind to P₁ and P₄ pockets, respectively, in the HLA-DR2 molecule. Three other amino acids, Asn94, Ile95 and Thr97, were identified as the secondary MHC-contact residues binding to the P₆, P₇ and P₉ pockets, respectively (21). Both MBP 85–99 and NAD 104–118 have identical residues in all the above positions, except that Thr97 in MBP 85–99 is substituted with Leu116 in NAD 104–118 [Figure 1A(ii)]. To understand the structural characteristics of MHC binding, we derived a homology model for NAD 104–118/HLA-DR2, which agreed well with the reference structure (Figure 1B), with an overall root mean square deviation of 0.70 Å for all atoms (Figure 1C). Expectedly, the side chains of the conserved Phe 92/111 in MBP 85–99/NAD 104–118 superposed well, and the distance between their alpha carbon atoms was 1.3 Å (Figure 1D). Likewise, while the orientation of Asn (94/113) in MBP 85–99/NAD 104–118 was comparable (1.4 Å), the side chains of Val (89/108) and Ile (95/114) were shifted, and their C-alpha positions were 3.2 and 1.5 Å, respectively (Figure 1D). The position shifts were consistent with energy minimization, and all the identical residues retained their ability to bind in appropriate pockets. The homology model also provided additional information on TCR-contact residues. Previously, it was shown that Phe91 and Lys93 in MBP 85–99 are the major TCR-contact residues, whereas His90 is less criti-
To determine the disease-inducing ability of NAD 108–120, we used active immunization and adoptive transfer EAE protocols. We immunized groups of mice and followed the disease course for 30 days. The CNS tissues were collected for histology during remission or upon termination of experiments. We noted that NAD 108–120 induced the disease dose dependently, in that a dose of 50 μg per mouse did not induce the disease, whereas the disease severity was moderate in animals that received 100 μg (Figure 2A). In contrast, a dose of 200 μg NAD 108–120 resulted in EAE severity comparable to that induced by MBP 89–101, with a similar mean day of onset (12.00 ± 1.32 versus 12.10 ± 0.94) and mean maximum
score (1.90 ± 0.23 versus 2.00 ± 0.15) [Table 1(i)], including the cumulative scores (16.00 ± 2.54 versus 18.00 ± 2.87) [Figure 2C(ii)]. Consistent with clinical EAE, mice that received NAD 108–120 showed dose-dependent perivascular infiltrations in the brains and spinal cords, and the inflammatory foci in animals that received 200 μg of NAD 108–120 were comparable to those immunized with MBP 89–101 [Table 1(i)]. Likewise, regardless of the immunogens used, inflammatory changes were found in both meninges and parenchyma, with a tendency for lesions to be seen more in meninges than parenchyma as evaluated at different time points (day 16 or 30) post-immunization, and the infiltrations were composed predominantly of lymphocytes, with few histiocytes and plasma cells [Figure 3A]. Verification of these results in naive mice did not reveal any of the changes described above (data not shown). We next verified encephalitogenic potential of NAD 108–120 in adoptive transfer experiments by injecting the lymphoblasts obtained from mice immunized with the corresponding peptides as described previously (24, 25). As shown in Figure 2B, LNC from mice immunized with MBP 89–101 or NAD 108–120 induced the disease in all the naive SJL recipients (100%) with comparable mean days of onset (11.40 ± 0.51 versus 11.80 ± 0.73) and mean maximum scores (2.20 ± 0.20 versus 2.00 ± 0) [Table 1(ii)]. The disease severity, however, tended to be lower in mice that received cells from NAD 108–120 than those that received MBP 89–101 sensitized cells as evaluated based on cumulative scores (12.60 ± 1.69 versus 16.60 ± 1.81) [Figure 2C(ii)] and the inflammatory foci in CNS tissues [Table 1(ii); Figure 3B]. Taken together, the data suggest that NAD 108–120 is an encephalitogenic mimicry epitope of MBP 89–101 and disease induction requires the mediation of antigen-sensitized T cells.

**MBP 89–101 and NAD 108–120 induce cross-reactive T-cell responses**

Induction of EAE with MBP 89–101 in SJL mice is typically mediated by CD4 cells (8, 22, 26). The fact that CNS inflammation induced by NAD 108–120 was similar to that induced by MBP 89–101 suggests that the mimicry epitope can induce the generation of cross-reactive T cells for MBP 89–101. To examine this possibility, we stimulated LNC from mice immunized with NAD 108–120 or MBP 89–101 with the corresponding peptides dissolved in 1× PBS, and their recall responses were measured based on [3H]thymidine incorporation. Expectedly, both MBP 89–101 and NAD 108–120 induced the dose-dependent proliferative responses to the respective peptides, but a fraction of these cells also responded to unimmunizing peptides (Figure 4). For example, LNC from MBP 89–101 immunized mice responded to MBP peptide, and approximately one-third of the MBP-reactive T cells also showed response to NAD 108–120 [Figure 4A (i)]. Similar patterns were observed when NAD 108–120 sensitized LNC were examined for their reactivity to NAD and MBP peptides although the reactivity for the latter was relatively low [Figure 4A (ii)]. The responses were antigen specific since LNC from mice immunized with either MBP 89–101 or NAD 108–120 did not respond to the control peptide (TMEV 70–86). We verified these data by second-round of re-stimulation with MBP 89–101 or NAD 108–120. Expectedly, LNC cultures prepared from MBP 89–101 immunized mice responded dose dependently to both MBP 89–101 (7.9-fold) and NAD 108–120 [4.9-fold; Figure 4B(i)]. Similar patterns were noted when the cultures obtained from NAD 108–120 immunized mice were re-stimulated with NAD 108–120 (2.9-fold) and MBP 89–101 [2.8-fold; Figure 4B(ii)]. The data demonstrate that MBP 89–101 and NAD 108–120 induce antigen-specific cross-reactive T-cell responses.

**LNC sensitized with MBP 89–101 or NAD 108–120 produce cytokines that favor CNS autoimmune**

The hallmark of encephalitogenic T cells is their ability to secrete T1 and T17 cytokines; in addition, mice deficient in GM-CSF show resistance to the development of EAE (27–29). We examined Th1 (IL-2 and IFN-γ), T2 (IL-4 and IL-10), T17 (IL-17A, IL-17F and IL-22) cytokines and GM-CSF in LNC obtained from mice immunized with MBP 89–101 or NAD 108–120 by both intracellular cytokine detection and cytokine ELISA. Figure 5(A) shows that the cells capable of secreting all the cytokines tested except IL-4 were present in the cultures stimulated with MBP 89–101 or NAD 108–120. Their proportions were dominated by both T17 (12.25 ± 2.14 versus 11.18 ± 2.65) and T17 (9.05 ± 1.32 versus 6.13 ± 1.23) cytokine-secreting cells (Figure 5A and B). Within the T17 subset, however, frequencies of IL-22 secreting cells were higher than IL-17F and IL-17A or combination of the two.
haplotype (HLA-DRB*1501, DQB1*0602) (5, 33, 34). Indeed, MBP 85–99 has been recognized as one of the major im-
candiate autoantigens identified in EAE/MS pathogenesis through the generation of cross-reactive T cells for MBP 89–101. MBP is one of the major cell-reactive T cells. However, the inflammatory foci in the CNS region of NAD 108–120 has a high degree of similarity with the core motif of the 10-amino acid fragment within MBP 85–99 (VHVFFKNIVT) represents an epitope center for recognition by both MHC/TCR and auto-antibodies; for the latter, however, the FFK sequence has to be conserved (5). Similar to MBP 85–99, NAD 108–120 also possesses all the major MHC- and TCR-contact residues but the question is whether it can elicit cross-reactive T cells and trigger CNS autoimmunity in humans. To address this possibility, we derived a homology model for NAD 104–118/HLA-DR2 to determine whether the configuration and orientations of the critical MHC-and TCR-contact residues in cognate and mimicry epitopes follow similar patterns. The homology model indicated that orientation of the side chains of the two critical MHC-anchor residues Ph92/111 and Asn94/113 and one major TCR-con-
tact residue, Phe91/110 in MBP 85–99/NAD 104–118 super-
posed comparably suggesting that the mimicry epitope can potentially anchor HLA-DR2 molecule similar to MBP 85–99 and also to be recognized by MBP 85–99 specific TCR. We also propose that NAD 108–120 has the potential to activate MBP-specific B cells. We make this prediction because the stretch of three amino acids, FFK within the epitope center of MBP 85–99 (VHVFFKNIVT) is highly critical for MBP-specific auto-antibody recognition (5). Ironically, microbial peptides bearing sequences identical to the epitope center of MBP 85–99 have been previously shown to bind MBP-specific auto-antibodies derived from MS brain tissue and the binding correlated with the number of identical residues in the epitope center (5). These include one peptide from L2 protein of human papillomavirus (VHFFK-I), which bound best to MBP-specific antibody followed by the peptides derived from Bacillus subtilis (FFFKNI) and Clostridium cellulare (FFKN). The fact that NAD 108–120 also possesses identical residues similar to the above (V-FFKNI) suggests that NAD 108–120 can also bind to MBP-specific auto-antibodies.

In this study, using both active and AT-EAE protocols, we show that NAD 108–120 induces autoimmune encephalomyelitis in SJL mice by generating cross-reactive T cells for MBP 89–101 and the T cells preferentially produce T H1 and T H17 cytokines that favor CNS autoimmunity. The induction of cross-reactive T cell responses was expected because the core region of NAD 108–120 has a high degree of similarity with MBP 89–101. This region potentially contains critical MHC- TCR-contact residues as shown in human MBP 85–99 (21), which might have led to the generation of cross-reactive T cells for MBP. However, the inflammatory foci in the CNS

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Clinical disease incidence (%)</th>
<th>Mean day of onset</th>
<th>Mean maximum score</th>
<th>No. of inflammatory foci</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) EAE induction by active immunization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MBP 89–101</td>
<td>200 µg</td>
<td>9/11 (81.8)</td>
<td>12.10 ± 0.94</td>
<td>2 ± 0.15</td>
</tr>
<tr>
<td>NAD 108–120</td>
<td>9/11 (81.8)</td>
<td>11.8 ± 0.73</td>
<td>2 ± 0</td>
<td>6 ± 2.51</td>
</tr>
<tr>
<td>50 µg</td>
<td>2/4 (50)</td>
<td>0</td>
<td>0</td>
<td>1 ± 0.71</td>
</tr>
<tr>
<td>100 µg</td>
<td>3/4 (75)</td>
<td>14 ± 0.00</td>
<td>1 ± 0.00</td>
<td>6.5 ± 4.57</td>
</tr>
<tr>
<td>200 µg</td>
<td>11/11 (100)</td>
<td>12 ± 1.32</td>
<td>1.09 ± 0.23</td>
<td>9.09 ± 3.80</td>
</tr>
</tbody>
</table>

(ii) EAE induction by adoptive transfer

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Clinical disease incidence (%)</th>
<th>Mean day of onset</th>
<th>Mean maximum score</th>
<th>No. of inflammatory foci</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBP 89–101</td>
<td>5/5(100)</td>
<td>11.4 ± 0.51</td>
<td>2.2 ± 0.2</td>
<td>10.4 ± 6.65</td>
</tr>
<tr>
<td>NAD 108–120</td>
<td>5/5(100)</td>
<td>11.8 ± 0.73</td>
<td>2 ± 0</td>
<td>6 ± 2.51</td>
</tr>
</tbody>
</table>

Scoring scale: 0, healthy; 1, decreased tail and body tone; 2, a clumsy but otherwise normal gait; 3, definite weakness of one or more limbs; 4, a paraplegic or monoplegic state; 5, a premorbid state.

Numbers are mean ± SEM.

*Represents only mice that showed clinical disease.

T cells sensitized with MBP 89–101 or NAD 108–120 use similar TCR vβs

To determine whether T cells sensitized with cognate and mimicry epitopes use similar TCR vβs, we analyzed their usage in CD4 T cells in cultures prepared from mice immunized with the corresponding peptides by FC. We noted that expression of TCRvβs were found consistently in the order of vβ4, vβ2, vβ17a, vβ6, vβ14, vβ3, vβ7, vβ5.1 and vβ5.2 in the cultures stimulated with either MBP 89–101 or NAD 108–120 (Figure 5A). Nonetheless, comparison of MBP-versus NAD-

Table 1. Clinical and histologic EAE in SJL mice induced with MBP 89–101 and NAD 108–120

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Clinical disease incidence (%)</th>
<th>Mean day of onset</th>
<th>Mean maximum score</th>
<th>No. of inflammatory foci</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) EAE induction by active immunization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MBP 89–101</td>
<td>200 µg</td>
<td>9/11 (81.8)</td>
<td>12.10 ± 0.94</td>
<td>2 ± 0.15</td>
</tr>
<tr>
<td>NAD 108–120</td>
<td>9/11 (81.8)</td>
<td>11.8 ± 0.73</td>
<td>2 ± 0</td>
<td>6 ± 2.51</td>
</tr>
<tr>
<td>50 µg</td>
<td>2/4 (50)</td>
<td>0</td>
<td>0</td>
<td>1 ± 0.71</td>
</tr>
<tr>
<td>100 µg</td>
<td>3/4 (75)</td>
<td>14 ± 0.00</td>
<td>1 ± 0.00</td>
<td>6.5 ± 4.57</td>
</tr>
<tr>
<td>200 µg</td>
<td>11/11 (100)</td>
<td>12 ± 1.32</td>
<td>1.09 ± 0.23</td>
<td>9.09 ± 3.80</td>
</tr>
</tbody>
</table>

(ii) EAE induction by adoptive transfer

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Clinical disease incidence (%)</th>
<th>Mean day of onset</th>
<th>Mean maximum score</th>
<th>No. of inflammatory foci</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBP 89–101</td>
<td>5/5(100)</td>
<td>11.4 ± 0.51</td>
<td>2.2 ± 0.2</td>
<td>10.4 ± 6.65</td>
</tr>
<tr>
<td>NAD 108–120</td>
<td>5/5(100)</td>
<td>11.8 ± 0.73</td>
<td>2 ± 0</td>
<td>6 ± 2.51</td>
</tr>
</tbody>
</table>

Scoring scale: 0, healthy; 1, decreased tail and body tone; 2, a clumsy but otherwise normal gait; 3, definite weakness of one or more limbs; 4, a paraplegic or monoplegic state; 5, a premorbid state.

Numbers are mean ± SEM.

*Represents only mice that showed clinical disease.

In this report, we present evidence that NAD 108–120 induces autoimmune encephalomyelitis through the generation of cross-reactive T cells for MBP 89–101. MBP is one of the major candidate autoantigens identified in EAE/MS pathogenesis (2, 30). The mouse MBP sequence spanning amino acids 89–101 has been shown to induce EAE in SJL mice (8, 31, 32), and the human MBP 85–99 sequence equivalent to mouse MBP 89–101 matches 100%. Numerous studies indicate that T cells and B cells from MS patients show reactivity to MBP; in addition, MBP 85–99 has been recognized as one of the major immunodominant epitopes in MS patients bearing HLA-DR2 haplotype (HLA-DRB*1501, DQB1*0602) (5, 33, 34). Indeed,
Mimicry Epitope for MBP 89–101 Induces EAE in SJL Mice

...cytokines induced with MBP 89–101 or NAD 108–120 follow the same pattern as above, the IL-22-secreting cells dominated Th17 responses. While IL-17 and IL-22 participate in innate immune responses (35, 36), IL-22 can exert both pro- and anti-inflammatory effects, but the role of IL-22 in organ-specific autoimmune diseases is controversial. For example, IL-22 potentiates chronic inflammatory diseases such as arthritis, inflammatory bowel disease and psoriasis but not CNS inflammation in the mouse model of EAE (37–41). Endothelial cells in the blood-brain barrier, however, express receptors for IL-17 and IL-22, and both cytokines can promote CD4 T-cell recruitment in MS lesions (42). On the contrary, IL-22 mediates protection in T-cell-mediated hepatitis and autoimmune myocarditis (40, 43, 44). The finding that IL-22 is a T-cell-derived cytokine, the receptors for which are abundantly expressed in the non-lymphoid tissues, suggests that IL-22 can modulate inflammatory responses in the local milieu (36). Alternatively, multiple cytokines might cooperatively regulate CNS inflammation.
ity that cognate and mimicry epitopes sensitize distinct T-cell clones (20). One possibility could be that skewed expansion of T-cell clones expressing particular TCR vbs influences the disease outcome, depending on the clones’ disease-inducing abilities. Alternatively, exposure to mimicry epitopes might lead to the expansion of hidden clones not usually responsive to cognate peptides. To address these possibilities, we evaluated TCR vβ usage of CD4 cells sensitized with MBP 89–101 or NAD 108–120, but we did not observe any striking differences between the two. Nonetheless, T cells expressing TCR vβ4, vβ2, vβ17a, vβ6, vβ14 and vβ3 were dominant in the cultures stimulated with either peptide, and these profiles were similar to those observed in PLP 139–151-sensitized cells (20, 45, 46). The data suggest that autoreactive T-cell responses generated in a given mouse strain tend to follow a similar pattern of TCR vβ usage regardless of the immunogens used.

MS is a complex disease and no known etiological agents have been identified. Two major factors have been implicated in the initiation of the disease: genetic susceptibility and exposure to environmental factors (2). In support of the latter, exacerbations of MS attacks or temporal alterations in the disease course have been linked to exposure primarily to virus infections such as EBV and HHV-6, but the clinical evidence remains elusive (12–14). The current dogma is that MS does not appear to follow Koch’s postulates in that

We recently reported that the TCR vβ usage of cross-reactive cells for PLP 139–151 induced with ACA 83–95 differs from those induced with PLP 139–151, suggesting a possibility that cognate and mimicry epitopes sensitize distinct T-cell clones (20). One possibility could be that skewed expansion of T-cell clones expressing particular TCR vbs influences the disease outcome, depending on the clones’ disease-inducing abilities. Alternatively, exposure to mimicry epitopes might lead to the expansion of hidden clones not usually responsive to cognate peptides. To address these possibilities, we evaluated TCR vβ usage of CD4 cells sensitized with MBP 89–101 or NAD 108–120, but we did not observe any striking differences between the two. Nonetheless, T cells expressing TCR vβ4, vβ2, vβ17a, vβ6, vβ14 and vβ3 were dominant in the cultures stimulated with either peptide, and these profiles were similar to those observed in PLP 139–151-sensitized cells (20, 45, 46). The data suggest that autoreactive T-cell responses generated in a given mouse strain tend to follow a similar pattern of TCR vβ usage regardless of the immunogens used.
no single organism appears to trigger MS; rather, exposure to multiple organisms might be critical for MS predisposition (2). We recently reported that ACA contains a mimicry epitope, ACA 83–95, for PLP 139–151, which induces a typical relapsing and remitting type of paralysis in SJL mice by generating PLP-specific T cells (19). In this report, we present evidence that ACA also contains a mimicry epitope, NAD 108–120, but this peptide induces EAE through the generation of T cells that cross-react with yet another myelin antigen, MBP 89–101. While ACA 83–95 is a derivative of rhodanese-related sulfur transferase of Acanthamoeba, NAD 108–120 represents NAD, which has been recognized as one of the virulent factors of ACA (47, 48). Presently, it is not known whether these amoebic proteins are processed and present ACA 83–95 and NAD 108–120 in animals infected with Acanthamoeba. Proving that mice infected with Acanthamoeba show ACA 83–95 or NAD 108–120/NAD 104–118 reactive T cells implies that the amoebic peptides are processed and presented naturally by the APCs. There is an indication that mice infected with ACA show the generation of myelin-and ACA-reactive T cells (Massilamany C., et al, unpublished results). However, it has been shown that the brains of mice infected with Acanthamoeba culbertsoni show increased expression of amoebic NAD mRNA (47), and the abundant availability of this amoebic protein can potentially generate cross-reactive immune responses for MBP locally. ACA is a natural CNS pathogen of humans, and while most individuals are exposed to Acanthamoeba as indicated by the presence of amoeba-reactive antibodies, they can remain asymptomatic, but the amoebae can induce granulomatous encephalitis in immunocompromised individuals. Whether such exposures can lead to CNS autoimmunity in genetically susceptible individuals remains to be tested. Based on our homology model, we predict that MS patients showing T-cell and antibody reactivity to MBP could also react to mimicry epitope by cross-reactivity. Experiments are underway to analyze cerebrospinal fluid samples obtained from MS patients to determine the presence of Acanthamoeba-specific genomic material or antibodies.

In conclusion, we show that ACA, in addition to possessing a mimicry epitope for PLP 139–151 (19), also contains NAD 108–120 as the mimicry epitope for MBP 89–101. The fact that ACA contains two mimicry epitopes for two different myelin antigens suggests that ACA infection can potentially lead to the generation of multiple myelin-reactive T cells. MS is a multifactorial disease characterized by a plethora of symptoms in the affected individuals, and the proposal that exposure to multiple microbes is a requirement for MS predisposition is gaining importance (2). It is tempting to speculate whether microbes similar to Acanthamoeba bearing the mimicry sequences for multiple myelin antigens are likely to be the candidates of disease initiation. To our knowledge, this is the first report to demonstrate that a solitary microbe contains mimicry sequences for more than one autoantigen in the target organs of their natural predilection in the infected individuals. Acanthamoeba are free-living organisms and are ubiquitous in the environment, leading to constant exposure. It is possible that such a co-existence can help microbes acquire some of the genetic elements of their hosts as an evasive mechanism for survival. Alternatively, exposure to such organisms could lead to a break in self-tolerance as a result of antigenic mimicry in genetically susceptible individuals who potentially carry pathogenic autoreactive T-cell and B-cell repertoires.

Acknowledgements
We thank Dr Jean-Jack Riethoven for statistical analysis of the data.

References


